Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 407 participants.
Also called NCT01907854
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 407 participants
- Sponsor
- Registry
-
NCT01907854 -
2012-004931-22 -
CTRI/2014/05/004623
-
- Other papers using this trial's data
- Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Hungary, India, Israel, Puerto Rico, Spain
- Registry status
- Completed
Technical summary
Registry record NCT01907854. Randomized; double masking; primary purpose treatment. Start 2013-12-02 (actual); primary completion 2015-06-15 (actual). Results posted on 2016-07-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin
- Acronym
- LIRA-SWITCH™
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- liraglutide
- Intervention (Drug)
- sitagliptin
- Intervention (Drug)
- placebo
- Intervention (Drug)
- placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01907854- Content hash
94c72548f175c9f108ef01c4c27c377179bfa96ef541cab95dc131273e950a9d